Roche Pharmaceuticals China announced that China's State Drug Administration has officially approved Luoshijia® single-dose pre-filled injections for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular oedema secondary to retinal venous obstruction.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.